Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.9K
Overview
67.9K
Tissue Transplantation01:24

Tissue Transplantation

350
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
350
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

317
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WTC 2025 Highlights: Infectious Disease.

Transplantation·2026
Same author

Pretransplant screening for infections in lung and heart transplant candidates.

JHLT open·2025
Same author

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Correction: Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.

Frontiers in immunology·2025
Same author

Disseminated Varicella-Zoster Virus Infection in Organ Transplant Recipients: A 10-year Retrospective Study.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jun 16, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K

Cell-mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multicenter

Javier T Solera1, Victor H Ferreira1, Carlos Cervera2

  • 1Ajmera Transplant Center, University Health Network, Toronto, ON, Canada.

Transplantation
|August 20, 2024
PubMed
Summary

The Quantiferon-CMV (QTF-CMV) assay can guide Cytomegalovirus (CMV) prophylaxis duration in high-risk transplant recipients. This cell-mediated immunity (CMI) testing is beneficial for recipient-seropositive patients but not donor-seropositive/recipient-seronegative patients.

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

12.7K

Related Experiment Videos

Last Updated: Jun 16, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

12.7K

Area of Science:

  • Transplant Immunology
  • Virology
  • Clinical Medicine

Background:

  • Limited interventional studies exist on using cell-mediated immunity (CMI) to guide antiviral prophylaxis.
  • Cytomegalovirus (CMV) remains a significant concern in organ transplant recipients.

Purpose of the Study:

  • To assess the Quantiferon-CMV (QTF-CMV) assay's utility in guiding CMV prophylaxis duration.
  • To evaluate the impact of CMI-guided prophylaxis on CMV viremia in high-risk transplant recipients.

Main Methods:

  • A single-arm, multicenter prospective study involved high-risk kidney, pancreas, liver, and heart transplant recipients.
  • QTF-CMV assay was used to test CMI at 3, 4, 5, and 6 months post-transplant.
  • Prophylaxis was discontinued upon positive CMI, continued on negative CMI, with CMV viremia ≥1000 IU/mL as the primary endpoint.

Main Results:

  • Of 108 patients, 89 completed the study. In donor-seropositive/recipient-seronegative (D+/R-) patients, only 2.6% showed positive CMI.
  • In recipient-seropositive (R+/ATG) patients, 66% had positive CMI, allowing early prophylaxis discontinuation.
  • Early discontinuation in R+/ATG patients was associated with lower rates of CMV viremia (12.1% vs. 35.3%).

Conclusions:

  • QTF-CMV-guided prophylaxis is effective for recipient-seropositive (R+/ATG) patients, enabling tailored prophylaxis duration.
  • This CMI-guided strategy is not beneficial for donor-seropositive/recipient-seronegative (D+/R-) patients.